相似文献
1
Cis interactions of immunoreceptors with MHC and non-MHC ligands.
Nat Rev Immunol. 2008 Apr;8(4):269-78. doi: 10.1038/nri2278. Epub 2008 Feb 29.
2
Non-MHC-restricted CD4+ T lymphocytes are regulated by HLA-Cw7-mediated inhibition.
Hum Immunol. 2000 Dec;61(12):1219-32. doi: 10.1016/s0198-8859(00)00218-4.
3
Killing of human immunodeficiency virus-infected primary T-cell blasts by autologous natural killer cells is dependent on the ability of the virus to alter the expression of major histocompatibility complex class I molecules.
Blood. 2004 Oct 1;104(7):2087-94. doi: 10.1182/blood-2004-02-0696. Epub 2004 Apr 29.
4
The role of cell surface recognition structures in the initiation of MHC-unrestricted 'promiscuous' killing by T cells.
Immunol Today. 1989 Nov;10(11):375-81. doi: 10.1016/0167-5699(89)90271-5.
5
Clonal analysis of human cytotoxic T lymphocytes: T4+ and T8+ effector T cells recognize products of different major histocompatibility complex regions.
Proc Natl Acad Sci U S A. 1982 Jul;79(14):4395-9. doi: 10.1073/pnas.79.14.4395.
6
Structural immunology and crystallography help immunologists see the immune system in action: how T and NK cells touch their ligands.
IUBMB Life. 2009 Jun;61(6):579-90. doi: 10.1002/iub.208.
7
The CD94/NKG2-A inhibitory receptor complex is involved in natural killer cell-mediated recognition of cells expressing HLA-G1.
J Immunol. 1997 Jun 15;158(12):5736-43.
8
TCR-independent cytokine stimulation induces non-MHC-restricted T cell activity and is negatively regulated by HLA class I.
Eur J Immunol. 2006 Sep;36(9):2347-58. doi: 10.1002/eji.200535387.
9
A bird's eye view of NK cell receptor interactions with their MHC class I ligands.
Immunol Rev. 2015 Sep;267(1):148-66. doi: 10.1111/imr.12319.
10
Transgenic expression of the Ly49A natural killer cell receptor confers class I major histocompatibility complex (MHC)-specific inhibition and prevents bone marrow allograft rejection.
J Exp Med. 1996 Nov 1;184(5):2037-41. doi: 10.1084/jem.184.5.2037.
引用本文的文献
1
Immune checkpoint blockade for cancer therapy: current progress and perspectives.
J Zhejiang Univ Sci B. 2025 Mar 13;26(3):203-226. doi: 10.1631/jzus.B2300492.
2
Targeting immune checkpoints on myeloid cells: current status and future directions.
Cancer Immunol Immunother. 2025 Jan 3;74(2):40. doi: 10.1007/s00262-024-03856-6.
3
Recognition of Self and Viral Ligands by NK Cell Receptors.
Immunol Rev. 2025 Jan;329(1):e13435. doi: 10.1111/imr.13435.
4
Single-cell mapping of leukocyte immunoglobulin-like receptors in kidney transplant rejection.
Front Transplant. 2022 Aug 11;1:952785. doi: 10.3389/frtra.2022.952785. eCollection 2022.
5
Current Landscape of Cancer Immunotherapy: Harnessing the Immune Arsenal to Overcome Immune Evasion.
Biology (Basel). 2024 Apr 28;13(5):307. doi: 10.3390/biology13050307.
6
Epithelial recognition and elimination against aberrant cells.
Semin Immunopathol. 2024 Jan;45(4-6):521-532. doi: 10.1007/s00281-024-01001-0. Epub 2024 Feb 27.
7
Recent advances in understanding TCR signaling: a synaptic perspective.
Fac Rev. 2023 Oct 16;12:25. doi: 10.12703/r/12-25. eCollection 2023.
8
Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer.
Front Immunol. 2023 Sep 13;14:1240275. doi: 10.3389/fimmu.2023.1240275. eCollection 2023.
9
Rapid cloning of antigen-specific T-cell receptors by leveraging the cis activation of T cells.
Nat Biomed Eng. 2022 Jul;6(7):806-818. doi: 10.1038/s41551-022-00874-6. Epub 2022 Apr 7.
10
Epithelial cells remove precancerous cells by cell competition via MHC class I-LILRB3 interaction.
Nat Immunol. 2021 Nov;22(11):1391-1402. doi: 10.1038/s41590-021-01045-6. Epub 2021 Oct 22.
本文引用的文献
1
The heterodimeric assembly of the CD94-NKG2 receptor family and implications for human leukocyte antigen-E recognition.
Immunity. 2007 Dec;27(6):900-11. doi: 10.1016/j.immuni.2007.10.013.
2
Structural basis of Dscam isoform specificity.
Nature. 2007 Sep 27;449(7161):487-91. doi: 10.1038/nature06147. Epub 2007 Aug 26.
3
Cis binding between inhibitory receptors and MHC class I can regulate mast cell activation.
J Exp Med. 2007 Apr 16;204(4):907-20. doi: 10.1084/jem.20060631. Epub 2007 Apr 9.
4
Bidirectional Eph-ephrin signaling during axon guidance.
Trends Cell Biol. 2007 May;17(5):230-8. doi: 10.1016/j.tcb.2007.03.004. Epub 2007 Apr 8.
5
Siglecs and their roles in the immune system.
Nat Rev Immunol. 2007 Apr;7(4):255-66. doi: 10.1038/nri2056.
6
Stable masking by H-2Dd cis ligand limits Ly49A relocalization to the site of NK cell/target cell contact.
Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):3978-83. doi: 10.1073/pnas.0607418104. Epub 2007 Feb 26.
7
Interactions of Ly49 family receptors with MHC class I ligands in trans and cis.
J Immunol. 2007 Feb 1;178(3):1277-84. doi: 10.4049/jimmunol.178.3.1277.
8
Quantifying the reduction in accessibility of the inhibitory NK cell receptor Ly49A caused by binding MHC class I proteins in cis.
Eur J Immunol. 2007 Feb;37(2):516-27. doi: 10.1002/eji.200636693.
9
Ly49B is expressed on multiple subpopulations of myeloid cells.
J Immunol. 2006 Nov 1;177(9):5840-51. doi: 10.4049/jimmunol.177.9.5840.
10
Variable dimerization of the Ly49A natural killer cell receptor results in differential engagement of its MHC class I ligand.
J Mol Biol. 2006 Sep 8;362(1):102-13. doi: 10.1016/j.jmb.2006.07.005. Epub 2006 Aug 8.
Zotero 插件